HUP0002469A2 - Solid thermoformable controlled-release pharmaceutical composition - Google Patents

Solid thermoformable controlled-release pharmaceutical composition

Info

Publication number
HUP0002469A2
HUP0002469A2 HU0002469A HUP0002469A HUP0002469A2 HU P0002469 A2 HUP0002469 A2 HU P0002469A2 HU 0002469 A HU0002469 A HU 0002469A HU P0002469 A HUP0002469 A HU P0002469A HU P0002469 A2 HUP0002469 A2 HU P0002469A2
Authority
HU
Hungary
Prior art keywords
controlled
pharmaceutical composition
release pharmaceutical
thermoformable
solid
Prior art date
Application number
HU0002469A
Other languages
English (en)
Inventor
Gilles Briault
Gerald Pichon
Herve Rolland
Francois Tharrault
Patrick Wuthrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9547360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0002469(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of HU0002469D0 publication Critical patent/HU0002469D0/hu
Publication of HUP0002469A2 publication Critical patent/HUP0002469A2/hu
Publication of HUP0002469A3 publication Critical patent/HUP0002469A3/hu
Publication of HU229342B1 publication Critical patent/HU229342B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/745—Polymers of hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
HU0002469A 1999-06-28 2000-06-28 Solid thermoformable delayed-release pharmaceutical composition HU229342B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9908210A FR2795326B1 (fr) 1999-06-28 1999-06-28 Composition pharmaceutique solide thermoformable a liberation controlee

Publications (4)

Publication Number Publication Date
HU0002469D0 HU0002469D0 (en) 2000-08-28
HUP0002469A2 true HUP0002469A2 (en) 2002-06-29
HUP0002469A3 HUP0002469A3 (en) 2008-04-28
HU229342B1 HU229342B1 (en) 2013-11-28

Family

ID=9547360

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002469A HU229342B1 (en) 1999-06-28 2000-06-28 Solid thermoformable delayed-release pharmaceutical composition

Country Status (23)

Country Link
US (1) US6319520B1 (hu)
EP (1) EP1064935B2 (hu)
JP (2) JP2001031591A (hu)
KR (1) KR100554899B1 (hu)
CN (1) CN1174744C (hu)
AT (1) ATE395045T1 (hu)
AU (1) AU765885B2 (hu)
BR (1) BR0002880A (hu)
CA (1) CA2312545C (hu)
CY (1) CY1110351T1 (hu)
DE (1) DE60038848D1 (hu)
DK (1) DK1064935T4 (hu)
EA (1) EA003751B1 (hu)
ES (1) ES2307489T5 (hu)
FR (1) FR2795326B1 (hu)
HK (1) HK1033435A1 (hu)
HU (1) HU229342B1 (hu)
NO (1) NO331449B1 (hu)
NZ (1) NZ505431A (hu)
PL (1) PL202494B1 (hu)
PT (1) PT1064935E (hu)
SI (1) SI1064935T2 (hu)
ZA (1) ZA200003245B (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013667A1 (en) * 1998-09-08 2000-03-16 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
FR2818550B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Composition pharmaceutique solide thermoformable pour la liberation controle de perindopril
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
US6764505B1 (en) 2001-04-12 2004-07-20 Advanced Cardiovascular Systems, Inc. Variable surface area stent
US7862495B2 (en) 2001-05-31 2011-01-04 Advanced Cardiovascular Systems, Inc. Radiation or drug delivery source with activity gradient to minimize edge effects
US7247313B2 (en) * 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US7175873B1 (en) 2001-06-27 2007-02-13 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US6656216B1 (en) 2001-06-29 2003-12-02 Advanced Cardiovascular Systems, Inc. Composite stent with regioselective material
GB0117619D0 (en) * 2001-07-19 2001-09-12 Phoqus Ltd Pharmaceutical dosage form
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
US7622146B2 (en) * 2002-07-18 2009-11-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US7169178B1 (en) * 2002-11-12 2007-01-30 Advanced Cardiovascular Systems, Inc. Stent with drug coating
US9579286B2 (en) 2003-04-21 2017-02-28 Purdue Pharma L.P. Tamper resistant dosage form comprising co-extruded, sequestered adverse agent particles and process of making same
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
MEP3608A (en) 2003-08-08 2011-05-10 Biovail Lab Int Srl Modified-release tablet of bupropion hydrochloride
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US7198675B2 (en) 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
KR101053558B1 (ko) 2004-03-30 2011-08-03 유로-셀띠끄 소시에떼 아노님 흡착제 및 억제제를 포함하는 내변조성 제형
WO2006004719A2 (en) 2004-06-25 2006-01-12 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
EP1978936B1 (de) * 2006-02-03 2013-07-10 Evonik Röhm GmbH Pharmazeutische Zusammensetzungen, enthaltend Mischungen aus Polymeren und in Wasser schlecht löslichen Wirkstoffen
BRPI0709344A2 (pt) * 2006-03-20 2011-07-12 Duramed Pharmaceuticals Inc anel intravaginal comprimido flexìvel, seu uso e processo de preparação, método de fornecer um agente ativo, kit terapêutico e produto
US8069814B2 (en) 2006-05-04 2011-12-06 Advanced Cardiovascular Systems, Inc. Stent support devices
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8048448B2 (en) 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
EP2150525A1 (en) * 2007-05-01 2010-02-10 Concert Pharmaceuticals Inc. Naphthyl(ethyl) acetamides
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
WO2012130837A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Solid agomelatine in non-crystalline form
EP2550863A1 (de) * 2011-07-27 2013-01-30 Bayer Intellectual Property GmbH Aktivstoffhaltige Partikel auf Polyacrylat-Basis
JP2014525423A (ja) * 2011-08-30 2014-09-29 ウニベルシテイト ヘント 多層放出配合物
EP2872129B1 (en) 2012-07-16 2017-03-08 ratiopharm GmbH Complex of agomelatine and cyclodextrin
JO3339B1 (ar) * 2012-09-11 2019-03-13 Shanghai Inst Pharmaceutical Ind شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
KR101659983B1 (ko) * 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
PT2810656T (pt) 2013-06-06 2017-11-13 Zentiva As Formulações de agomelatina compreendendo agomelatina na forma de cocristais
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
CN103724415B (zh) * 2013-12-31 2015-05-27 中山大学 斜带石斑鱼性别调控基因Rspo1及其制备方法和应用
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
FR3070619A1 (fr) * 2017-09-01 2019-03-08 Ab7 Innovation Piece moulee monolithique en matrice multiple pour la diffusion d’actifs et son procede d’obtention
EP3459527B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
AU2018361503A1 (en) * 2017-11-02 2020-05-14 Ishihara Sangyo Kaisha, Ltd. Sustained-release medical composition
KR101856911B1 (ko) * 2017-12-13 2018-05-10 동국대학교 산학협력단 펠루비프로펜의 서방성 고체분산체 제제 및 이의 제조방법
CN109985025B (zh) * 2017-12-29 2023-01-13 沈阳药科大学 具有pH触发释药特征的眼部缓释给药系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
DE4138513A1 (de) * 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
WO1997008950A1 (en) † 1995-09-07 1997-03-13 Fuisz Technologies, Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
DE19539362A1 (de) † 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
DE19728516C2 (de) * 1997-07-04 1999-11-11 Sanol Arznei Schwarz Gmbh TTS zur Verabreichung von Levonorgestrel und gegebenenfalls Estradiol
FR2766088B1 (fr) * 1997-07-17 2001-01-05 Dow Corning Sa Dispositifs a liberation controlee d'un agent pharmaceutique, leur fabrication par co-extrusion et article intermediaire
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee

Also Published As

Publication number Publication date
NO331449B1 (no) 2012-01-02
DK1064935T3 (da) 2008-08-25
PL341042A1 (en) 2001-01-02
AU765885B2 (en) 2003-10-02
EP1064935B2 (fr) 2011-06-08
NO20003349L (no) 2000-12-29
EP1064935B1 (fr) 2008-05-14
HK1033435A1 (en) 2001-08-31
FR2795326A1 (fr) 2000-12-29
EA003751B1 (ru) 2003-08-28
ATE395045T1 (de) 2008-05-15
EA200000584A2 (ru) 2000-12-25
ES2307489T5 (es) 2011-11-07
SI1064935T1 (sl) 2008-08-31
SI1064935T2 (sl) 2011-12-30
JP2001031591A (ja) 2001-02-06
DE60038848D1 (de) 2008-06-26
HUP0002469A3 (en) 2008-04-28
EA200000584A3 (ru) 2001-04-23
CA2312545A1 (fr) 2000-12-28
HU229342B1 (en) 2013-11-28
BR0002880A (pt) 2001-01-30
CY1110351T1 (el) 2015-04-29
EP1064935A1 (fr) 2001-01-03
JP2006077033A (ja) 2006-03-23
NZ505431A (en) 2002-12-20
CA2312545C (fr) 2006-09-12
KR20010049643A (ko) 2001-06-15
PL202494B1 (pl) 2009-06-30
ZA200003245B (en) 2001-01-17
NO20003349D0 (no) 2000-06-27
FR2795326B1 (fr) 2001-08-31
AU4273400A (en) 2001-01-04
KR100554899B1 (ko) 2006-02-24
CN1285188A (zh) 2001-02-28
CN1174744C (zh) 2004-11-10
DK1064935T4 (da) 2011-09-26
US6319520B1 (en) 2001-11-20
ES2307489T3 (es) 2008-12-01
HU0002469D0 (en) 2000-08-28
PT1064935E (pt) 2008-07-03

Similar Documents

Publication Publication Date Title
HUP0002469A3 (en) Solid thermoformable controlled-release pharmaceutical composition
PL351387A1 (en) Pharmaceutical composition
HUP0202513A3 (en) Betha-carboline pharmaceutical compositions
GB0028088D0 (en) Pharmaceutical compositions
GB0001662D0 (en) Pharmaceutical compositions
IL146632A0 (en) Pharmaceutical tablets
GB9923436D0 (en) Pharmaceutical compositions
ZA200000857B (en) Pharmaceutical composition.
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
IL145632A0 (en) Pharmaceutical compounds
GB9904163D0 (en) Pharmaceutical compositions
EG23937A (en) Novel pharmaceutical
GB9916434D0 (en) Pharmaceutical compounds
HK1046140A1 (zh) 固體藥劑
GB9911017D0 (en) Pharmaceutical compositions
GB9914255D0 (en) Pharmaceutical compounds
GB9909041D0 (en) Novel pharmaceutical
GB9903784D0 (en) Pharmaceutical compounds
HUP0202652A3 (en) Pharmaceutical carrier composition
EG23946A (en) Novel pharmaceutical
GB9904911D0 (en) Pharmaceutical compositions
GB2373499B (en) Pharmaceutical compounds
GB9902651D0 (en) Pharmaceutical compositions
GB9916210D0 (en) Pharmaceutical composition
GB9916413D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees